UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 11.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 268,203 shares of the biotechnology company's stock after selling 33,278 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.28% of Sarepta Therapeutics worth $33,496,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Blueshift Asset Management LLC bought a new stake in shares of Sarepta Therapeutics in the 3rd quarter valued at $262,000. Finepoint Capital LP lifted its holdings in Sarepta Therapeutics by 0.5% in the third quarter. Finepoint Capital LP now owns 133,535 shares of the biotechnology company's stock valued at $16,677,000 after buying an additional 700 shares during the period. Quantbot Technologies LP bought a new stake in Sarepta Therapeutics during the third quarter valued at $237,000. Qsemble Capital Management LP acquired a new stake in Sarepta Therapeutics during the 3rd quarter worth about $311,000. Finally, Fisher Asset Management LLC raised its position in shares of Sarepta Therapeutics by 1.3% in the 3rd quarter. Fisher Asset Management LLC now owns 18,155 shares of the biotechnology company's stock worth $2,267,000 after acquiring an additional 239 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock traded down $0.25 during mid-day trading on Thursday, hitting $126.28. 608,676 shares of the stock were exchanged, compared to its average volume of 1,239,228. Sarepta Therapeutics, Inc. has a 12 month low of $85.61 and a 12 month high of $173.25. The company has a 50-day simple moving average of $122.61 and a 200 day simple moving average of $131.37. The company has a market capitalization of $12.06 billion, a P/E ratio of 101.22 and a beta of 0.77. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Wall Street Analyst Weigh In

SRPT has been the subject of several recent analyst reports. Robert W. Baird decreased their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a research note on Thursday, November 7th. William Blair upgraded shares of Sarepta Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th. Evercore ISI cut their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a research note on Thursday, November 7th. Citigroup decreased their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a "neutral" rating for the company in a research note on Thursday, August 8th. Finally, StockNews.com lowered Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $175.55.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.